NASDAQ
1 days, 12 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Receives Nasdaq Letter Regarding Clawback Policy Compliance, Matter Now Closed
Sharps Technology received a letter from Nasdaq regarding a delay in adopting a Clawback Policy, but Nasdaq has since confirmed the company is now in compliance and the matter is closed.
Delay expected
 
Worse than expected
 
NASDAQ
4 days, 12 hours ago 
STSS
Sharps Technology INC
10-K/A: Sharps Technology Files Amendment to 10-K to Include Compensation Recovery Policy
Sharps Technology, Inc. files an amendment to its annual report on Form 10-K to include the company's Compensation Recovery Policy.
NASDAQ
5 days, 12 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Inc. Announces Exercise of 97% of Class B Cashless Warrants
Sharps Technology, Inc. reports the exercise of 97% of its Class B cashless warrants as of April 14, 2025, following a public offering in January 2025.
NASDAQ
15 days, 12 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Faces Delisting Threat After Failing to Meet Nasdaq's Stockholders' Equity Requirement
Sharps Technology Inc. received a delisting notification from Nasdaq due to non-compliance with the $2.5 million stockholders' equity requirement.
Worse than expected
 
NASDAQ
16 days, 13 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Inc. Reports on Warrant Exercises Following Public Offering
Sharps Technology, Inc. announces the exercise of Class B Warrants following a previously reported public offering in January 2025.
NASDAQ
17 days, 13 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Stockholders Vote on Reverse Stock Split and Warrant Issuance
Sharps Technology held a special meeting where stockholders voted on a reverse stock split proposal and the authorization of warrant issuance.
Worse than expected
 
Capital raise
 
NASDAQ
18 days, 12 hours ago 
STSS
Sharps Technology INC
Form 4: Sharps Technology CEO Increases Stake in Company
Robert Michael Hayes, CEO of Sharps Technology Inc., reports acquiring additional shares of common stock through open market purchases.
Better than expected
 
NASDAQ
22 days, 18 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Stockholders Approve Warrant Issuance, Triggering Reduced Exercise Price
Sharps Technology stockholders approved the issuance of certain warrants and shares, leading to a reduced warrant exercise price of $0.292.
NASDAQ
23 days, 12 hours ago 
STSS
Sharps Technology INC
10-K: Sharps Technology Reports FY24 Results, Navigates Financial Challenges and Sets Stage for Potential Revenue in 2025
Sharps Technology reports a net loss for FY24, focuses on expanding production capacity, and anticipates potential revenue generation in the second half of 2025.
Delay expected
 
Worse than expected
 
Capital raise
 
NASDAQ
30 days, 21 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Urges Shareholders to Vote for Reverse Stock Split to Maintain Nasdaq Listing
Sharps Technology is reminding shareholders to vote in favor of a reverse stock split to maintain its Nasdaq listing and avoid delisting to the OTC Markets.
Worse than expected
 
NASDAQ
36 days, 13 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Faces Nasdaq Delisting Notice Due to Minimum Bid Price Non-Compliance
Sharps Technology, Inc. received a delisting notice from Nasdaq due to its failure to maintain a minimum bid price of $1.00 per share, and the company plans to appeal the decision.
Worse than expected
 
NASDAQ
67 days, 12 hours ago 
STSS
Sharps Technology INC
DEF 14A: Sharps Technology Seeks Stockholder Approval for Reverse Stock Split and Warrant Issuance to Maintain Nasdaq Listing
Sharps Technology is asking stockholders to approve a reverse stock split and the issuance of warrants to comply with Nasdaq listing requirements and raise capital.
Capital raise
 
NASDAQ
79 days, 12 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Completes $20 Million Public Offering to Fuel Growth
Sharps Technology successfully closed a $20 million public offering to fund debt repayment, working capital, and general corporate activities.
Capital raise
 
NASDAQ
81 days, 22 hours ago 
STSS
Sharps Technology INC
S-1MEF: Sharps Technology Files Amendment to Increase Securities Offering
Sharps Technology has filed an amendment to its registration statement to increase the amount of securities offered, aiming to raise additional capital.
Capital raise
 
NASDAQ
82 days, 12 hours ago 
STSS
Sharps Technology INC
S-1/A: Sharps Technology Files Amendment No. 3 to Form S-1 Registration Statement
Sharps Technology, Inc. files an amendment to its Form S-1 registration statement to update exhibit information related to warrants and other agreements.
Capital raise
 
NASDAQ
82 days, 16 hours ago 
STSS
Sharps Technology INC
S-1/A: Sharps Technology Issues Series A and B Common Stock Warrants
Sharps Technology, Inc. has filed documents detailing the terms of Series A and B warrants for the purchase of common stock.
Capital raise
 
NASDAQ
87 days, 12 hours ago 
STSS
Sharps Technology INC
S-1/A: Sharps Technology Seeks $15 Million in Unit Offering to Bolster Working Capital
Sharps Technology aims to raise capital through a unit offering, including common stock and warrants, to fund working capital and repay debt.
Capital raise
 
NASDAQ
88 days, 10 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology Amends Bylaws, Clarifying Stockholder Quorum Requirements
Sharps Technology, Inc. amended its bylaws on January 21, 2025, to clarify that one-third of stockholders constitutes a quorum for stockholder meetings.
NASDAQ
99 days, 11 hours ago 
STSS
Sharps Technology INC
S-1: Sharps Technology Inc. Announces Proposed Public Offering of Units
Sharps Technology Inc. plans to offer up to 6,726,457 units, each including common stock and warrants, or pre-funded units as an alternative.
Worse than expected
 
Delay expected
 
Capital raise
 
NASDAQ
117 days, 11 hours ago 
STSS
Sharps Technology INC
8-K: Sharps Technology, Inc. Announces Results of Annual Meeting and Shareholder Votes
Sharps Technology, Inc. held its annual meeting, electing directors, ratifying the accounting firm, and approving the 2024 Equity Incentive Plan.
STSS 
Sharps Technology INC 
NASDAQ

S-1/A: Sharps Technology Files Amendment No. 3 to Form S-1 Registration Statement

Sentiment:
 S-1/A Filing
 27 January 2025 4:35 PM

Sharps Technology, Inc. files an amendment to its Form S-1 registration statement to update exhibit information related to warrants and other agreements.

Capital raise
  The document details the terms of Series A and Series B warrants, which are often issued in connection with a capital raise.  The warrants provide the holders with the right to purchase common stock at a specified exercise price, potentially bringing additional capital to the company upon exercise.  The filing fee calculation table indicates a proposed maximum offering price of $72,450,000 for the securities being registered, suggesting a significant capital raise. 

Summary
  • Sharps Technology, Inc. has filed Amendment No. 3 to its Form S-1 registration statement.
  • The amendment primarily updates Item 16 of Part II to update Exhibit 107, which pertains to filing fees.
  • The document includes the forms for Series A and Series B warrants, detailing their terms, exercise conditions, and potential adjustments.
  • The Series A warrants have a 60-month termination date after stockholder approval, while Series B warrants have a 30-month termination date.
  • Both warrants include provisions for cashless exercise, price adjustments due to stock dividends, splits, and subsequent equity sales, as well as adjustments in the event of a fundamental transaction.
  • The warrants also contain clauses regarding stockholder approval, transferability, and limitations on the holder's ability to exercise the warrant if it would result in exceeding a beneficial ownership limitation of 4.99% or 9.99%.
Sentiment

Score: 6

Explanation: The document is a legal filing outlining the terms of warrants. It is neutral in tone, but the issuance of warrants can be seen as a moderately positive sign as it provides the company with potential future capital.

Highlights
  • Sharps Technology, Inc. filed an amendment to its Form S-1 registration statement.
  • The amendment updates exhibit information, specifically Exhibit 107, related to filing fees.
  • The document includes the form of Series A and Series B warrants, outlining their terms and conditions.
  • Series A warrants have a termination date 60 months after the Stockholder Approval Date.
  • Series B warrants have a termination date 30 months after the Stockholder Approval Date.
  • Both warrants allow for cashless exercise under certain conditions.
  • The exercise price of the warrants is subject to adjustments based on stock dividends, splits, and subsequent equity sales.
  • The warrants include provisions for adjustments in the event of a fundamental transaction, such as a merger or sale of assets.
  • The warrants contain a beneficial ownership limitation of 4.99% or 9.99%.
Positives
  • The warrants provide flexibility for holders through cashless exercise options.
  • The exercise price is subject to adjustments that protect the holder's investment in the event of stock dilutions or corporate actions.
  • The warrants include provisions to ensure the holder receives equivalent value in the event of a fundamental transaction.
  • The company is obligated to seek stockholder approval for certain warrant-related actions, providing shareholders with a voice.
Negatives
  • The warrants contain a beneficial ownership limitation, which may restrict the holder's ability to fully exercise the warrant.
  • The exercise price is subject to adjustments that could potentially increase the price under certain circumstances.
  • The warrants' value is dependent on the company's stock performance and market conditions.
Risks
  • The value of the warrants is subject to market fluctuations and the company's performance.
  • The company's failure to obtain stockholder approval for certain warrant-related actions could impact the warrant's terms.
  • Dilution of common stock could occur due to the exercise of these and other warrants.
  • The beneficial ownership limitation may restrict the holder's ability to fully realize the potential value of the warrants.
Future Outlook

The company intends to hold a special meeting of stockholders no later than 60 calendar days after the closing date to obtain stockholder approval for the warrants.

Industry Context

The filing of warrant agreements is a common practice for companies seeking to raise capital, particularly in the biotechnology and pharmaceutical sectors. These warrants provide investors with the potential for future gains based on the company's stock performance.

Comparison to Industry Standards
  • The terms and conditions outlined in the Series A and Series B warrants are generally consistent with industry standards for similar financing instruments.
  • The inclusion of provisions for cashless exercise, price adjustments, and fundamental transactions is typical in warrant agreements to protect the interests of both the company and the warrant holders.
  • Comparable companies, such as those in the biotechnology or pharmaceutical industries that have issued warrants, often include similar clauses to ensure fair value and protect against dilution.
Stakeholder Impact
  • Shareholders may experience dilution if the warrants are exercised.
  • Warrant holders have the potential to profit if the company's stock price increases.
  • The company may benefit from the additional capital raised upon warrant exercise.
  • The company's financial flexibility could be enhanced by the potential for future capital infusions.
Next Steps
  • The company needs to hold a special meeting of stockholders to obtain approval for certain warrant-related actions.
  • The company will need to monitor the stock price and market conditions to determine the optimal timing for warrant exercises.
  • The company must ensure compliance with all applicable securities laws and regulations related to the issuance and exercise of the warrants.
Key Dates
  • June 10, 2020: Date of Asset/Share Purchase Agreement among the Company, Safegard Medical (Hungary) Ktf,, Numan Holding Ltd, Cortrus Services SA and Latitude Investments Limited
  • June 24, 2020: Date of Amendment No. 1 to Asset/Share Purchase Agreement
  • August 27, 2020: Date of Amendment No. 2 to Asset/Share Purchase Agreement
  • October 28, 2020: Date of Amendment No. 3 to Asset/Share Purchase Agreement
  • January 1, 2021: Date of Consulting Agreement between the Company and Berry Berler
  • July 19, 2021: Date of Amendment No. 4 to Asset/Share Purchase Agreement
  • September 9, 2021: Date of Employment Agreement between the Company and Robert Hayes
  • September 23, 2021: Date of Letter from Numan Holding Ltd
  • December 14, 2021: Date of Note Purchase Agreement among the Company and the purchasers named therein
  • February 28, 2022: Date of Amendment No. 5 to Asset/Share Purchase Agreement
  • March 22, 2022: Date of Plan and Agreement of Merger between Sharps Technology, Inc., a Wyoming corporation, and Sharps Technology, Inc., a Nevada corporation
  • April 13, 2022: Date of Amendment No. 6 to Asset/Share Purchase Agreement
  • May 28, 2019: Date of Amended Consulting Agreement between the Company and Barry Berler
  • July 11, 2017: Date of Royalty Agreement between Alan Blackman and Barry Berler
  • September 4, 2018: Date of Amendment to Royalty Agreement
  • September 29, 2022: Date of Agreement by and among Sharps Technology, Inc., InjectEZ, LLC, Nephron Pharmaceuticals Corporation, Nephron SC, Inc. and Nephron Sterile Compounding Center LLC
  • December 8, 2022: Date of Distribution Agreement by and among Sharps Technology, Inc., Nephron Pharmaceuticals Corporation and Nephron SC, Inc.
  • December 28, 2022: Date of Certificate of Amendment to Designation, filed on December 22, 2022
  • September 27, 2023: Date of PIPE Agreement, Rd Agreement, Registration Rights Agreement, and Placement Agent Agreement
  • January 27, 2023: Date of 2023 Equity Incentive Plan
  • January 27, 2025: Date of the signature of the registration statement on Form S-1
Keywords
warrants, common stock, exercise price, stockholder approval, registration statement, securities, dilution, fundamental transaction, cashless exercise, beneficial ownership
STSS 
Sharps Technology INC 
NASDAQ
Sector: TBD
 
Filings with Classifications
Worse than expected
18 April 2025 5:25 PM
Current Report
  • The company failed to adopt the Clawback Policy in a timely manner, which is worse than expected for a Nasdaq-listed company.
Delay expected
18 April 2025 5:25 PM
Current Report
  • The company delayed the adoption of the Clawback Policy.
Worse than expected
4 April 2025 5:00 PM
8-K Filing
  • The company failed to meet the minimum stockholders' equity requirement for continued listing on the NASDAQ.
Worse than expected
2 April 2025 4:05 PM
Current Report
  • The reverse stock split proposal failed to pass, which may limit the company's ability to meet Nasdaq listing requirements or improve its stock price.
Capital raise
2 April 2025 4:05 PM
Current Report
  • The company consummated an offering and sale of securities on January 29, 2025.
  • Stockholders voted to authorize the issuance of warrants and shares of common stock underlying the warrants in connection with this offering.
Better than expected
1 April 2025 5:24 PM
SEC Form 4 Filing
  • The CEO increasing his stake in the company is a positive signal.
Delay expected
27 March 2025 5:30 PM
Annual Results
  • The Company has delayed the commercialization of the Sharps Provensa product line.
  • The products specialized technology requires further design and assembly optimization, which requires further capital investment and not currently budgeted.
Capital raise
27 March 2025 5:30 PM
Annual Results
  • The company completed a $20 million offering in January 2025.
  • The company entered into subscription agreements with certain institutional investors in December 2024.
  • The company entered into a securities purchase agreement and Senior Secured Note for an aggregate principal amount of $4.375 million in September 2024.
  • The company completed two simultaneous offerings in September 2023.
  • The company completed a securities purchase agreement with institutional investors in February 2023.
Worse than expected
27 March 2025 5:30 PM
Annual Results
  • The company has not generated any revenue to date.
  • The company reported a net loss of $9.3 million for the year ended December 31, 2024.
  • The company forfeited a $1 million escrow deposit related to a terminated asset acquisition agreement.
Worse than expected
20 March 2025 8:38 AM
8-K Filing / Press Release
  • The company is at risk of being delisted from the Nasdaq stock exchange.
Worse than expected
14 March 2025 4:17 PM
8-K Filing
  • The company received a delisting notice from Nasdaq due to its failure to maintain a minimum bid price of $1.00 per share.
Capital raise
11 February 2025 4:05 PM
Proxy Statement
  • The company consummated a public offering on January 29, 2025, issuing units consisting of common stock, Series A Warrants, and Series B Warrants.
  • The company also issued pre-funded units consisting of pre-funded warrants, Series A Warrants, and Series B Warrants.
  • The company received net proceeds of approximately $18.2 million from the offering.
  • The company intends to use the net proceeds from the Offering for working capital and other general corporate purposes and to repay the principal amount of $4,375,000 in outstanding senior notes of the Company.
Capital raise
30 January 2025 4:30 PM
Capital Markets Transaction Announcement
  • Sharps Technology completed a public offering of common stock and warrants, raising approximately $20 million in gross proceeds.
  • The offering included 14,285,714 common units or pre-funded units, each consisting of common stock or a pre-funded warrant, a Series A warrant, and a Series B warrant.
  • Aegis Capital Corp. exercised its over-allotment option with respect to 2,142,857 Series A Warrants and 2,142,857 Series B Warrants.
Capital raise
28 January 2025 6:08 AM
Securities Registration Amendment
  • The company is seeking to raise additional capital by offering units consisting of common stock and warrants.
  • The maximum aggregate offering price of the units together with pre-funded units is $20,000,000.
  • The total offering amount is $80,500,000 including common stock underlying the warrants.
Capital raise
27 January 2025 4:35 PM
S-1/A Filing
  • The document details the terms of Series A and Series B warrants, which are often issued in connection with a capital raise.
  • The warrants provide the holders with the right to purchase common stock at a specified exercise price, potentially bringing additional capital to the company upon exercise.
  • The filing fee calculation table indicates a proposed maximum offering price of $72,450,000 for the securities being registered, suggesting a significant capital raise.
Capital raise
27 January 2025 12:28 PM
Warrant Agreement
  • The warrants represent a potential future capital raise for the company as holders exercise their rights to purchase common stock.
  • The exercise of the warrants will result in the issuance of new shares, which will provide the company with additional capital.
Capital raise
22 January 2025 4:06 PM
S-1/A Filing
  • Sharps Technology is offering up to 8,108,108 units, each consisting of one share of common stock, one Series A warrant, and one Series B warrant.
  • The company is also offering pre-funded units as an alternative for purchasers who would exceed ownership limits, with each pre-funded unit containing a pre-funded warrant, a Series A warrant, and a Series B warrant.
  • The company intends to use the net proceeds for general corporate purposes, including working capital and investments, and to repay $4,174,658 in outstanding senior notes.
Worse than expected
10 January 2025 5:21 PM
Prospectus
  • The company has a history of losses and has not generated significant revenue from syringe sales to date, indicating worse than expected financial performance.
Delay expected
10 January 2025 5:21 PM
Prospectus
  • There continue to be delays in the commercialization of the Sharps Provensa product line.
Capital raise
10 January 2025 5:21 PM
Prospectus
  • The document details a proposed public offering of up to 6,726,457 units, each including common stock and warrants, or pre-funded units as an alternative.
  • The company intends to use the net proceeds from this offering for working capital and other general corporate purposes and to repay outstanding debt, including $4,174,658 in outstanding senior notes.
Capital raise
6 December 2024 9:22 AM
Capital Raise Announcement
  • Sharps Technology is raising capital through the sale of 248,430 shares of common stock.
  • The shares are priced at $1.95 each.
  • The company expects to receive gross proceeds of $484,438 before fees and commissions.
Capital raise
5 December 2024 10:57 AM
Shareholder Letter
  • The company is working with both government and private investment sources in Hungary to expand the current manufacturing footprint.
  • The company mentions the need to raise capital to fund continuing operations as a risk.
Delay expected
5 December 2024 10:57 AM
Shareholder Letter
  • The acquisition of the InjectEZ facility has been delayed due to business developments with the selling partner.
Better than expected
5 December 2024 10:57 AM
Shareholder Letter
  • The company has secured significant sales agreements that will fully utilize current manufacturing capacity and drive substantial revenue growth.
  • The company has regained compliance with NASDAQ listing rules, removing a potential risk.
Capital raise
5 December 2024 8:30 AM
Sales Agreement Announcement
  • The company mentions the need to raise capital to fund continuing operations.
  • The company is collaborating with both government and private investment sources in Hungary to expand the current manufacturing footprint.
Better than expected
5 December 2024 8:30 AM
Sales Agreement Announcement
  • The company has secured significant sales agreements and sold out its existing inventory, indicating better than expected demand for its products.
Worse than expected
14 November 2024 3:15 PM
Quarterly Report
  • The company reported zero revenue for the quarter, which is worse than expected for a company that has been operating for several years.
  • The company's working capital is insufficient to fund operations for the next 12 months, indicating a worsening financial situation.
  • The company is facing multiple legal challenges, which adds to the negative outlook.
Delay expected
14 November 2024 3:15 PM
Quarterly Report
  • There continue to be delays in the commercialization of the Sharps Provensa product line.
  • The products specialized technology requires further design and assembly optimization as identified in our previous commercialization efforts.
Capital raise
14 November 2024 3:15 PM
Quarterly Report
  • The company intends to finance its commercialization activities and its working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources.
  • The company completed a debt financing agreement for $4.375 million.
  • The company issued 190,773 shares of common stock in a Reg A offering.
  • The company issued 260,799 inducement warrants in connection with a warrant inducement program.
Worse than expected
15 October 2024 9:19 AM
Corporate Action Announcement
  • The reverse stock split is a result of the company's share price falling below the Nasdaq minimum bid price requirement, indicating a negative performance.
Worse than expected
30 September 2024 8:21 AM
Proxy Statement
  • The company needs to implement a reverse stock split to avoid being delisted from the NASDAQ, indicating that the share price is below the minimum bid price requirement.
Capital raise
30 September 2024 8:21 AM
Proxy Statement
  • The company expects to continue to be able to raise capital to grow the Company following the reverse stock split.
  • The company states that raising capital will likely be more challenging without shareholder approval of the reverse stock split.
Capital raise
30 September 2024 8:19 AM
Shareholder Communication
  • The company states that the reverse stock split will allow them to have more access to capital to pursue their management teams growth strategies.
  • The company expects to continue to be able to raise capital to grow the company following the reverse stock split.
Worse than expected
30 September 2024 8:19 AM
Shareholder Communication
  • The company is facing potential delisting from NASDAQ due to its stock price falling below the minimum bid price requirement, indicating worse than expected performance.
Delay expected
30 September 2024 8:19 AM
Shareholder Communication
  • The company had previously approved a 1-for-8 reverse stock split in July, but it was not implemented.
Capital raise
23 September 2024 8:13 AM
Bridge Financing Announcement
  • The company has entered into a secured bridge loan financing of approximately $3.5 million.
  • The financing includes the sale of secured notes and either common stock or pre-funded warrants.
  • The company has agreed to file one or more registration statements with the SEC covering the resale of the Common Stock and the Shares issuable upon exercise of the pre-funded warrants.
Worse than expected
4 September 2024 6:12 PM
Proxy Statement
  • The company needs to implement a reverse stock split to avoid being delisted from the Nasdaq, indicating that the company's stock price is below the minimum bid price requirement.
Worse than expected
14 August 2024 4:41 PM
Quarterly Report
  • The company's working capital is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
  • The company has not generated significant revenue from syringe sales to date.
  • The company's stock is facing potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price rule.
Delay expected
14 August 2024 4:41 PM
Quarterly Report
  • There continues to be delays in the commercialization of the Sharps Provensa product line.
Capital raise
14 August 2024 4:41 PM
Quarterly Report
  • The company intends to finance its commercialization activities and its working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources.
  • The company completed a Reg A offering and warrant inducement program in the second quarter of 2024, raising approximately $3.5 million in gross proceeds.
  • The company's stockholders approved an increase in authorized shares of common stock from 100,000,000 shares to 500,000,000 shares.
  • The company's stockholders approved a proposal to authorize the Board of Directors to effect a reverse stock split of shares of the Company's common stock, at a ratio of up to 1-for-8.
Capital raise
30 July 2024 4:05 PM
Corporate Action
  • The increase in authorized shares suggests a potential future capital raise through the issuance of new shares.
  • The company now has the capacity to issue up to 400 million additional shares of common stock.
Better than expected
25 July 2024 8:30 AM
Supply Agreement Announcement
  • The agreement is expected to generate over $50 million in revenue, which is a significant positive development for the company.
  • The agreement sells out the current manufacturing capacity of the EU facility, indicating strong demand for the company's products.
Capital raise
18 July 2024 5:10 PM
Special Meeting Results
  • The company has been authorized to issue securities in one or more non-public offerings.
  • These offerings can be at a discount of up to 20% below the market price of the common stock.
Worse than expected
15 July 2024 5:20 PM
Current Report
  • The company received a delisting notice from Nasdaq, indicating a failure to maintain the minimum stock price requirement.
Capital raise
15 July 2024 5:20 PM
Current Report
  • The company's stockholders approved a proposal for the issuance of securities in one or more non-public offerings.
  • The maximum discount at which the securities will be offered will be equivalent to a discount not to exceed 20% below the market price of the common stock.
Capital raise
9 July 2024 9:13 AM
Proxy Statement
  • The company is seeking to increase the authorized number of shares of common stock, if required for future equity transactions.
  • The company is seeking approval to issue securities in non-public offerings where the maximum discount will not exceed 20% below the market price of the company's common stock.
Capital raise
9 July 2024 9:11 AM
Shareholder Communication
  • The company is seeking authorization to increase the number of authorized shares of common stock.
  • The company is seeking authorization to issue securities in non-public offerings with a maximum discount of 20% below the market price.
Capital raise
3 July 2024 11:16 AM
Proxy Statement
  • The company is seeking approval to increase the authorized number of shares of common stock, which may be required for future equity transactions.
  • The company is also seeking approval to issue securities in non-public offerings where the maximum discount will be equivalent to a discount not to exceed 20% below the market price of the company's common stock.
Capital raise
3 July 2024 11:14 AM
Special Meeting Announcement
  • The company is seeking approval to increase the authorized number of shares of common stock, which may be used for future equity transactions.
  • The company is also seeking the ability to issue securities in non-public offerings, with a maximum discount of 20% below the market price of the company's common stock.
Capital raise
25 June 2024 6:18 PM
Proxy Statement
  • The company is seeking approval to issue securities in one or more non-public offerings.
  • The maximum discount at which securities will be offered will be equivalent to a discount of 20% below the market price of our common stock.
  • The company may seek to raise additional capital to implement our business strategy and enhance our overall capitalization.
Capital raise
17 June 2024 9:07 AM
Capital Raise Announcement
  • The company raised $850,820.00 through the sale of 2,239,000 common shares at $0.38 per share.
  • The company also received $330,000.00 from the exercise of 1,000,000 warrants.
  • The company issued 1,000,000 new warrants exercisable at $0.45 per share.
Capital raise
4 June 2024 9:19 AM
Capital Raise Announcement
  • The company raised $744,040 through the sale of 1,958,000 shares of common stock at $0.38 per share.
  • The company received $1,465,715 from the exercise of 4,441,715 warrants.
  • The company issued 4,441,715 new warrants exercisable at $0.45 per share.
Capital raise
3 June 2024 6:07 AM
Warrant Issuance Announcement
  • The company is issuing new warrants to raise capital.
  • The company expects to receive approximately $4,371,524 in gross proceeds if all new warrants are exercised.
  • The funds will be used for capital expenditures, working capital, and general corporate purposes.
Better than expected
31 May 2024 8:35 AM
Shareholder Update
  • The revised deal terms are better than the original agreement, including a reduced acquisition price and a secured $200 million sales agreement.
Capital raise
30 May 2024 12:17 PM
Warrant Issuance Announcement
  • The company is issuing new warrants with an exercise price of $0.45 per share.
  • The company expects to receive approximately $3,299,557 in gross proceeds if all new warrants are exercised.
  • The proceeds are intended for capital expenditures, working capital, and general corporate purposes.
Better than expected
28 May 2024 1:37 PM
Shareholder Letter
  • The company is experiencing increased interest in its products due to FDA recalls and tariffs on Chinese-made syringes, which is expected to lead to substantial revenue growth.
Better than expected
24 May 2024 4:15 PM
Material Definitive Agreement
  • The company has secured a significant purchase agreement with Nephron, guaranteeing a minimum of $188.5 million in revenue over five years.
  • The amended asset purchase agreement provides clarity on the cash consideration and eliminates a subordinated note, improving the financial terms of the deal.
Delay expected
24 May 2024 4:15 PM
Material Definitive Agreement
  • The original Asset Purchase Agreement did not close under its original terms, leading to the need for an amendment.
Capital raise
14 May 2024 4:21 PM
Quarterly Report
  • The company intends to finance its commercialization activities and working capital needs largely from the sale of equity securities.
  • The company's ability to continue as a going concern is dependent on its ability to raise sufficient financing.
Delay expected
14 May 2024 4:21 PM
Quarterly Report
  • There are ongoing delays in the commercialization of the Sharps Provensa product line due to the need for further design and assembly optimization.
Worse than expected
14 May 2024 4:21 PM
Quarterly Report
  • The company's net loss was worse than expected due to the lack of revenue and high operating expenses.
  • The company's cash balance and working capital are lower than expected, raising concerns about its ability to continue as a going concern.
Capital raise
29 March 2024 3:29 PM
Annual Results
  • The company intends to finance its future development and commercialization activities and its working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources.
  • The company completed a securities purchase agreement in February 2023 and two simultaneous offerings in September 2023 to raise capital.
Delay expected
29 March 2024 3:29 PM
Annual Results
  • There continues to be delays in the commercialization of the Sharps Provensa product line.
Worse than expected
29 March 2024 3:29 PM
Annual Results
  • The company's net loss increased significantly from $4.6 million in 2022 to $9.8 million in 2023.
  • The company has not generated any revenue to date, indicating a lack of commercial success.
Worse than expected
19 January 2024 4:25 PM
Current Report
  • The company has failed to maintain the minimum bid price and has been granted a second extension to regain compliance, indicating a continued struggle to meet listing requirements.

Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.